Nomura Holdings’s Akero Therapeutics AKRO Stock Holding History

Nomura Holdings’s Portfolio AKRO Stock Details AKRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-6,562	Closed	-$298K	–	1412
2025 Q1	$266K	Buy	+6,562	New	+$278K	﹤0.01%	1629
2024 Q4	–	Sell	-18,858	Closed	-$541K	–	2152
2024 Q3	$541K	Buy	+18,858	New	+$492K	﹤0.01%	1240
2024 Q2	–	Sell	-8,046	Closed	-$203K	–	1741
2024 Q1	$203K	Buy	+8,046	New	+$193K	﹤0.01%	1465

Other funds holding AKRO

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nomura Holdings's AKRO Position: Q2 2025 in Review

Nomura Holdings sold out of Akero Therapeutics (AKRO) in Q2 2025, closing a stake of 6,562 shares — an estimated $298K sold.

Nomura Holdings first reported a position in AKRO in Q1 2024 and held it in 3 quarters. The position peaked at $541K in Q3 2024. 257 funds tracked by Wall St. Rank hold AKRO as of Q2 2025.

Nomura Holdings reported no remaining Akero Therapeutics position as of Q2 2025 after selling out during the quarter.
Nomura Holdings sold 6,562 Akero Therapeutics shares in Q2 2025, an estimated $298K.
Nomura Holdings first reported a position in Akero Therapeutics in Q1 2024 and held it in 3 quarters.
Nomura Holdings's Akero Therapeutics position peaked at $541K in Q3 2024.
257 funds tracked by Wall St. Rank held Akero Therapeutics as of Q2 2025.

Based on Nomura Holdings's 13F filing for Q2 2025, filed 14 Aug 2025.